Neutral. Smallish deal vs $60bn revenue / $30bn EBITDA.
• Acquiring Capstan for $2.1bn cash. Gives access to CAR-T therapy and mRNA genetic engineering.
• Recently acquired Gubra but mainly in milestone payments.
• Largest acquisition since Cereval for $8.7bn 2023 which had disappointing Emraclidine trials.
• Low patent cliff exposure now that Humira has rolled off.
• Issued $4bn in Feb. Has $6bn maturing next year ($2bn May and $4bn Nov).
Find more articles and bullets on these widgets:
Aussie 10-yr futures rallied well on the RBA rate decision last week, reversing a small part of recent weakness. Recent price action pressured prices through to new pullback lows last week. Next support undercuts at 95.420 (pierced), the Feb 13 low, ahead of 95.275, the Nov 14 low and a key support. Clearance of this level would strengthen a bearish condition. To the upside, a recovery of recent losses would shift attention to resistance at 96.207, a Fibonacci retracement point.
US President Donald Trump is shortly due to deliver remarks in Pittsburgh, Pennsylvania, where he is expected to endorse Nippon Steel's takeover of US Steel. LIVESTREAM The announcement comes as the US and Japan remain far apart on a new bilateral trade deal.
We've just published our US Macro Weekly - Download Full Report Here
While the past week may be remembered for court decisions suspending the majority of the White House’s tariffs, it also brought further data evidence that the US economy did not fall off a cliff at the start of Q2.
